Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2020, Vol. 11 Issue (4) : 730-736     DOI: 10.14336/AD.2020.0621
Letter to the Editor |
Potential Using of Fat-derived Stromal Cells in the Treatment of Active Disease, and also, in Both Pre- and Post-Periods in COVID-19
Copcu Hasim Eray*
Mest Health Services, Aesthetic and Plastic Surgery, Izmir, Turkey
Download: PDF(271 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

The whole world is fighting with the COVID-19 pandemic, which traps people home, causing high business and economic losses, and above all, leads to very serious deaths. The lack of a valid, accepted treatment protocol and vaccine that leads to continued treatment searches. Leng et al published their article in the Aging and Disease journal, which demonstrates that mesenchymal stem cells (MSCs) can be used for COVID-19 treatment. Adipose tissue is one of the most important MSCs sources in the body, and adipose derived stromal cells (ADSCs) from adipose tissue are also one of the most valuable components of stromal vascular fraction (SVF). Finally, Gentile and Sterodimas, have also published their article for the potential use of SVF in COVID-19 treatment in Aging and Disease journal. Their publication has been a guide in many ways. Adipose tissue-derived stromal cells have three main features: Immunomodulatory, anti-inflammatory and regenerative. Immunomodulator effects are used as a preventive in patients prone to disease; its anti-inflammatory effects may allow them to be used as a therapeutic during active disease period and finally regenerative effects to repair post-disease sequale. Those cells can be obtained not only enzymatically, but also mechanically with very benefits. They can be delivered not only systemically through the IV route but also to the target organ with a carrier. While suggesting any adipose tissue-derived treatment method possibility, the relation of adipose tissue COVID-19 should not be ignored. Because, COVID-19 shows its effect through ACE-2 and adipose tissue is very rich and important tissue in terms of ACE-2.

Keywords COVID 19      stromal cells      stem cell      ADSC      adipose tissue     
Corresponding Authors: Copcu Hasim Eray   
About author:

These authors contributed equally to this work.

Just Accepted Date: 24 June 2020   Issue Date: 30 July 2020
E-mail this article
E-mail Alert
Articles by authors
Copcu Hasim Eray
Cite this article:   
Copcu Hasim Eray. Potential Using of Fat-derived Stromal Cells in the Treatment of Active Disease, and also, in Both Pre- and Post-Periods in COVID-19[J]. Aging and disease, 2020, 11(4): 730-736.
URL:     OR
[1] Morestin H (1915). Quelques cas de greffes graisseuse appliquees aIa chirurgie reparatrice. Bull Mem Soc Chir (Paris), 41:1631
[2] Jarrell BE, Williams SK, Stokes G, et al. (1986). Use of freshly isolated capillary endothelial cells for the immediate establishment of a monolayer on a vascular graft at surgery. Surgery, 100(2): 392-399.
[3] Zuk PA, Zhu M, Mizuno H, et al. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue engineering, 7(2): 211-228.
[4] Leng Z, Zhu R, Hou W, et al (2020). Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis, 11:216-228.
[5] Shetty AK (2020). Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia. Aging Dis, 11(2): 462-464.
[6] Ozturk S, Elcin AE, EWlcin YM (2020). Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes? Aging Dis, in press
[7] Chen J, Hu C, Chen L, et al (2020). Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering, in press.
[8] Gentile P, Sterodimas A (2020). Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-DiseaseAging Dis, 11(2)
[9] Schildberg FA, Donneberg VS (2018). Stromal cells in health and disease. Cytometry, 93(9):871-875
[10] Bourin P, Bunnell BA, Casteilla L, et al. (2013). Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy, 15(6): 641-648.
[11] Ullah M, Liu DD, Thakor AS (2019). Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience, 15: 421-438.
[12] Bari E, Ferrarotti I, Saracino L, et al. (2020). Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells, 9(4), E924.
[13] Zimmerlin L, Donnenberg VS, Rubin, et al. (2013). Mesenchymal markers on human adipose stem/progenitor cells. Cytometry. Part A, 83(1): 134-140.
[14] Al-Ghadban S, Bunnell BA (2020). Adipose Tissue-Derived Stem Cells: Immunomodulatory Effects and Therapeutic Potential. Physiology, 35(2):125-133.
[15] Fukui E, Funaki S, Kimura K, et al. (2019). Adipose Tissue-Derived Stem Cells Have the Ability to Differentiate into Alveolar Epithelial Cells and Ameliorate Lung Injury Caused by Elastase-Induced Emphysema in Mice. Stem cells international, 2019: 5179172.
[16] Silva JD, Lopes-Pacheco M, Paz A, et al. (2018). Mesenchymal Stem Cells From Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome. Critical care medicine, 46(2): e132-e140.
[17] Sun Z, Li F, Zhou X, et al. (2018). Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials. Journal of thoracic disease, 10(2): 1084-1098.
[18] Sesé B, Sanmartín, J M, Ortega B, et al. (2019). Nanofat Cell Aggregates: A Nearly Constitutive Stromal Cell Inoculum for Regenerative Site-Specific Therapies. Plastic and reconstructive surgery, 144(5): 1079-1088.
[19] Ghiasloo M, Lobato RC, Díaz JM, et al. (2020). Expanding Clinical Indications of Mechanically Isolated Stromal Vascular Fraction: A Systematic Review. Aesthetic surgery journal, in press
[20] Ryan PM, Caplice NM (2020). Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation and Cytokine Amplification in COVID-19. Obesity, in press.
[21] Li MO, Flavell RA (2008). Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity,28(4): 468-476.
[22] Khoury M, Cuenca J, Cruz FF, et al. (2020). Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19. European respiratory journal, in press.
[23] Lopes-Pacheco M, Robba C, Rocco P, et al. (2020). Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome. Cell biology and toxicology, 36(1):83-102.
[24] Garg RK, Rennert RC, Duscher D, et al. (2014). Capillary force seeding of hydrogels for adipose-derived stem cell delivery in wounds. Stem cells translational medicine, 3(9):1079-1089.
[25] Bari E, Ferrarotti I, Saracino L, et al. (2020). Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells, 9(4): E924.
[26] Hoogduijn MJ, Lombardo E (2019). Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review. Stem cells translational medicine, 8(11):1126-1134.
[27] Ji F, Li L, Li Z, et al. (2020). Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019. Stem cells translational medicine, in press.
[28] Zimmerlin L, Rubin JP, Pfeifer ME, et al (2013). Human adipose stromal vascular cell delivery in a fibrin spray. Cytotherapy, 15(1):102-108.
[29] Hoffmann M, Schroeder S, Kleine-Weber H, et al. (2020). Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrobial agents and chemotherapy, in press.
[30] Shetty R, Ghosh A, Honavar S, et al. (2020). Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. Indian journal of ophthalmology, 68(5):693-702.
[31] Engeli S, Gorzelniak K, Kreutz R, et al. (1999). Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 17: 555-560
[32] Karlsson C, Lindell K, Ottosson M, et al. (1998). Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab, 83: 3925-3929
[33] Pahlavani M, Kalupahana NS, Ramalingam, et al (2017). Regulation and Functions of the Renin-Angiotensin System in White and Brown Adipose Tissue. Comprehensive Physiology, 7(4):1137-1150.
[34] Slamkova M, Zorad S, Krskova K (2016). Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity. Endocrine regulations, 50(4):229-240.
[35] Jia X, Yin C, Lu S, et al. (2020). Two Things About COVID-19 Might Need Attention Preprints, in press.
[36] Slamkova M, Zorad S, Krskova K (2016). Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity. Endocr Regul, 50(4):229-240.
[1] Hyun-Doo Song, Sang Nam Kim, Abhirup Saha, Sang-Yeop Ahn, Seun Akindehin, Yeonho Son, Yoon Keun Cho, MinSu Kim, Ji-Hyun Park, Young-Suk Jung, Yun-Hee Lee. Aging-Induced Brain-Derived Neurotrophic Factor in Adipocyte Progenitors Contributes to Adipose Tissue Dysfunction[J]. Aging and disease, 2020, 11(3): 575-587.
[2] Pietro Gentile, Aris Sterodimas. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease[J]. Aging and disease, 2020, 11(3): 465-469.
[3] Selçuk Öztürk, Ayşe Eser Elçin, Yaşar Murat Elçin. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?[J]. Aging and disease, 2020, 11(3): 477-479.
[4] Zikuan Leng, Rongjia Zhu, Wei Hou, Yingmei Feng, Yanlei Yang, Qin Han, Guangliang Shan, Fanyan Meng, Dongshu Du, Shihua Wang, Junfen Fan, Wenjing Wang, Luchan Deng, Hongbo Shi, Hongjun Li, Zhongjie Hu, Fengchun Zhang, Jinming Gao, Hongjian Liu, Xiaoxia Li, Yangyang Zhao, Kan Yin, Xijing He, Zhengchao Gao, Yibin Wang, Bo Yang, Ronghua Jin, Ilia Stambler, Lee Wei Lim, Huanxing Su, Alexey Moskalev, Antonio Cano, Sasanka Chakrabarti, Kyung-Jin Min, Georgina Ellison-Hughes, Calogero Caruso, Kunlin Jin, Robert Chunhua Zhao. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and disease, 2020, 11(2): 216-228.
[5] Shijin Xia, Changxi Zhou, Bill Kalionis, Xiaoping Shuang, Haiyan Ge, Wen Gao. Combined Antioxidant, Anti-inflammaging and Mesenchymal Stem Cell Treatment: A Possible Therapeutic Direction in Elderly Patients with Chronic Obstructive Pulmonary Disease[J]. Aging and disease, 2020, 11(1): 129-140.
[6] Yazhen Zhang, Wenyi Chen, Bing Feng, Hongcui Cao. The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis[J]. Aging and disease, 2020, 11(1): 141-153.
[7] Zhongfeng Liu, Xuan Wang, Kewen Jiang, Xunming Ji, Y. Alex Zhang, Zhiguo Chen. TNFα-induced Up-regulation of Ascl2 Affects the Differentiation and Proliferation of Neural Stem Cells[J]. Aging and disease, 2019, 10(6): 1207-1220.
[8] Yuan Tan, Minjing Ke, Zhijian Huang, Cheong-Meng Chong, Xiaotong Cen, Jia-Hong Lu, Xiaoli Yao, Dajiang Qin, Huanxing Su. Hydroxyurea Facilitates Manifestation of Disease Relevant Phenotypes in Patients-Derived IPSCs-Based Modeling of Late-Onset Parkinson’s Disease[J]. Aging and disease, 2019, 10(5): 1037-1048.
[9] Brian Z Wang, Jane J Yang, Hongxia Zhang, Charity A Smith, Kunlin Jin. AMPK Signaling Regulates the Age-Related Decline of Hippocampal Neurogenesis[J]. Aging and disease, 2019, 10(5): 1058-1074.
[10] Linsha Ma, Jingchao Hu, Yu Cao, Yilin Xie, Hua Wang, Zhipeng Fan, Chunmei Zhang, Jinsong Wang, Chu-Tse Wu, Songlin Wang. Maintained Properties of Aged Dental Pulp Stem Cells for Superior Periodontal Tissue Regeneration[J]. Aging and disease, 2019, 10(4): 793-806.
[11] Yoorim Choi, Dong Suk Yoon, Kyoung-Mi Lee, Seong Mi Choi, Myon-Hee Lee, Kwang Hwan Park, Seung Hwan Han, Jin Woo Lee. Enhancement of Mesenchymal Stem Cell-Driven Bone Regeneration by Resveratrol-Mediated SOX2 Regulation[J]. Aging and disease, 2019, 10(4): 818-833.
[12] Min-jun Wang, Jiajia Chen, Fei Chen, Qinggui Liu, Yu Sun, Chen Yan, Tao Yang, Yiwen Bao, Yi-Ping Hu. Rejuvenating Strategies of Tissue-specific Stem Cells for Healthy Aging[J]. Aging and disease, 2019, 10(4): 871-882.
[13] Navneet Kumar Dubey, Hong-Jian Wei, Sung-Hsun Yu, David F. Williams, Joseph R. Wang, Yue-Hua Deng, Feng-Chou Tsai, Peter D. Wang, Win-Ping Deng. Adipose-derived Stem Cells Attenuates Diabetic Osteoarthritis via Inhibition of Glycation-mediated Inflammatory Cascade[J]. Aging and disease, 2019, 10(3): 483-496.
[14] Hongling Li, Junfen Fan, Linyuan Fan, Tangping Li, Yanlei Yang, Haoying Xu, Luchan Deng, Jing Li, Tao Li, Xisheng Weng, Shihua Wang, Robert Chunhua Zhao. MiRNA-10b Reciprocally Stimulates Osteogenesis and Inhibits Adipogenesis Partly through the TGF-β/SMAD2 Signaling Pathway[J]. Aging and disease, 2018, 9(6): 1058-1073.
[15] Junfen Fan, Xingyan An, Yanlei Yang, Haoying Xu, Linyuan Fan, Luchan Deng, Tao Li, Xisheng Weng, Jianmin Zhang, Robert Chunhua Zhao. MiR-1292 Targets FZD4 to Regulate Senescence and Osteogenic Differentiation of Stem Cells in TE/SJ/Mesenchymal Tissue System via the Wnt/β-catenin Pathway[J]. Aging and disease, 2018, 9(6): 1103-1121.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd